GLP-1 (Glucagon-like peptide-1) receptor agonists

GLP-1 (Glucagon-like peptide-1) receptor agonists are a class of medications originally developed to treat type 2 diabetes and obesity that mimic the naturally occurring incretin hormone GLP-1, and are currently under intensive investigation for their neuroprotective potential in Parkinson's disease.

Glucagon-like peptide-1 (GLP-1) is a hormone produced in the gut that stimulates insulin secretion, inhibits glucagon release, and slows gastric emptying in response to food intake. GLP-1 receptor agonists (GLP-1 RAs)—which include widely known medications such as exenatide, liraglutide, and semaglutide—are synthetically engineered to mimic this hormone while resisting rapid degradation by enzymes in the body. By binding to GLP-1 receptors, these drugs effectively regulate blood sugar and suppress appetite. Because of their profound efficacy, they have revolutionized the management of metabolic disorders.

• ### Context in Neurodegeneration

• While traditionally viewed through an endocrinological lens, GLP-1 receptors are also widely expressed throughout the central nervous system, including regions implicated in Parkinson's disease and Alzheimer's disease. In recent years, researchers discovered that activating these brain receptors triggers a cascade of neuroprotective effects. In laboratory models, GLP-1 RAs have been shown to reduce neuroinflammation, decrease oxidative stress, improve mitochondrial function, and promote the survival of dopaminergic neurons—the specific brain cells that progressively die off in Parkinson's disease.

This biological rationale has propelled GLP-1 RAs into the clinical trial pipeline for Parkinson's disease. Notably, early-stage clinical trials investigating exenatide in Parkinson's patients have demonstrated promising, albeit preliminary, results. Patients receiving the drug showed stabilization in motor and cognitive symptoms compared to those on a placebo, suggesting that the drug might be doing more than just masking symptoms—it may be slowing the underlying disease progression.

A class of medications originally developed to treat type 2 diabetes and obesity that mimic the incretin hormone GLP-1, currently under intensive investigation for their disease-modifying and neuroprotective potential in Parkinson's disease.

The exploration of GLP-1 receptor agonists in Parkinson's disease represents a critical paradigm shift in neurology. Currently, available Parkinson's treatments, such as levodopa, only manage symptoms and do not halt the neurodegenerative process. If GLP-1 RAs are proven effective in larger Phase 3 trials, they could become the first class of disease-modifying therapies for Parkinson's. Furthermore, because these drugs are already approved by regulatory agencies (like the FDA and EMA) for diabetes and weight management, their safety profiles are well-understood. This strategy of drug repurposing significantly accelerates the research timeline, offering accelerated hope to millions of patients worldwide.